Zai Lab Closes $30 Million C Funding Round

00:18 EDT 30 Jun 2017 | ChinaBio Today

Zai Lab, a Shanghai novel drug development/in-licensing company, raised $30 million in a Series C round. In early 2016, Zai Lab closed a much larger $100 million B financing. In less than four years, Zai Lab has in-licensed eight products, plus signed a deal to build a joint biological drug manufacturing facility in Suzhou with General Electric, started its own drug development program, and filed to raise $150 million for a venture fund. OrbiMed led the C round and was joined by new investors Vivo Capital, Cormorant and Rock Springs Capital. More details....

Share this with colleagues:  

Original Article: Zai Lab Closes $30 Million C Funding Round


More From BioPortfolio on "Zai Lab Closes $30 Million C Funding Round"

Quick Search


Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...